Bridgeway Capital Management’s Protara Therapeutics TARA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $181K | Buy |
59,830
+19,830
| +50% | +$60.1K | ﹤0.01% | 979 |
|
|
2025
Q1 | $170K | Buy |
40,000
+15,000
| +60% | +$63.9K | ﹤0.01% | 952 |
|
|
2024
Q4 | $132K | Sell |
25,000
-24,200
| -49% | -$128K | ﹤0.01% | 1074 |
|
|
2024
Q3 | $90K | Buy |
49,200
+25,000
| +103% | +$45.8K | ﹤0.01% | 1168 |
|
|
2024
Q2 | $50.3K | Sell |
24,200
-34,800
| -59% | -$72.4K | ﹤0.01% | 1220 |
|
|
2024
Q1 | $237K | Sell |
59,000
-5,000
| -8% | -$20.1K | ﹤0.01% | 1074 |
|
|
2023
Q4 | $120K | Hold |
64,000
| – | – | ﹤0.01% | 1214 |
|
|
2023
Q3 | $107K | Hold |
64,000
| – | – | ﹤0.01% | 1220 |
|
|
2023
Q2 | $153K | Hold |
64,000
| – | – | ﹤0.01% | 1185 |
|
|
2023
Q1 | $198K | Hold |
64,000
| – | – | 0.01% | 1109 |
|
|
2022
Q4 | $172K | Hold |
64,000
| – | – | ﹤0.01% | 1119 |
|
|
2022
Q3 | $189K | Hold |
64,000
| – | – | 0.01% | 1152 |
|
|
2022
Q2 | $188K | Hold |
64,000
| – | – | ﹤0.01% | 1104 |
|
|
2022
Q1 | $327K | Buy |
64,000
+10,500
| +20% | +$53.6K | 0.01% | 1048 |
|
|
2021
Q4 | $361K | Sell |
53,500
-59,000
| -52% | -$398K | 0.01% | 1056 |
|
|
2021
Q3 | $779K | Buy |
+112,500
| New | +$779K | 0.01% | 901 |
|
|
2017
Q3 | – | Sell |
-1,180
| Closed | -$73K | – | 1441 |
|
|
2017
Q2 | $73K | Sell |
1,180
-295
| -20% | -$18.3K | ﹤0.01% | 1375 |
|
|
2017
Q1 | $103K | Hold |
1,475
| – | – | ﹤0.01% | 1329 |
|
|
2016
Q4 | $112K | Hold |
1,475
| – | – | ﹤0.01% | 1355 |
|
|
2016
Q3 | $550K | Buy |
1,475
+554
| +60% | +$207K | 0.01% | 1051 |
|
|
2016
Q2 | $296K | Buy |
921
+625
| +211% | +$201K | ﹤0.01% | 1223 |
|
|
2016
Q1 | $92K | Hold |
296
| – | – | ﹤0.01% | 1381 |
|
|
2015
Q4 | $184K | Hold |
296
| – | – | ﹤0.01% | 1319 |
|
|
2015
Q3 | $165K | Hold |
296
| – | – | ﹤0.01% | 1337 |
|
|
2015
Q2 | $211K | Buy |
+296
| New | +$211K | ﹤0.01% | 1342 |
|